May 7 |
Grifols: Why To Watch From The Sidelines
|
Apr 19 |
Grifols 2023 Annual Report on Form 20-F filed with the SEC
|
Apr 18 |
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
|
Apr 15 |
Grifols reportedly looking to appoint independent directors
|
Apr 14 |
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
|
Apr 11 |
ATUS, ATHE and GRFS among pre-market losers
|
Apr 10 |
Grifols Plans First Bond Sale Since Short Seller Attack
|
Apr 4 |
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
|
Mar 22 |
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
Mar 21 |
Spanish regulators find no major errors in Grifols' accounting: report
|